Patents Assigned to Sciaticon AB
  • USE OF TNF-ALPHA INHIBITORS FOR TREATING A NERVE DISORDER MEDIATED BY NUCLEUS PULPOSUS
    Publication number: 20120244157
    Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
    Type: Application
    Filed: June 6, 2012
    Publication date: September 27, 2012
    Applicant: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of an antibody that blocks TNF-alpha activity for treating a nerve disorder mediated by nucleus pulposus
    Patent number: 8057792
    Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: November 15, 2011
    Assignee: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
    Patent number: 7906481
    Abstract: The present invention relates to a method for treating nerve disorders in a mammal or a vertebrate by administering a TNF-alpha inhibitor. The invention also relates to the use of a TNF-alpha inhibitor in the preparation of pharmaceutical compositions for the treatment of nerve root injury and other nerve disorders.
    Type: Grant
    Filed: January 3, 2007
    Date of Patent: March 15, 2011
    Assignee: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Soluble cytokine receptors TNF-? blocking antibodies for treating spinal disorders mediated by nucleus pulposus
    Patent number: 7811990
    Abstract: Described herein are methods and compositions for the treatment of spinal disorders mediated by nucleus pulposus. The compositions can include a soluble cytokine receptor and/or a TNF-? blocking antibody.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: October 12, 2010
    Assignee: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Thalidomide and thalidomide derivatives for treating spinal disorders mediated by nucleus pulposus
    Patent number: 7723357
    Abstract: Described herein are methods and compositions for the treatment of spinal disorders mediated by nucleus pulposus. The compositions can include thalidomide or a thalidomide derivative.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: May 25, 2010
    Assignee: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of TNF-alpha inhibitors for treating a nerve disorder mediated by nucleus pulposus
    Patent number: 7708995
    Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: May 4, 2010
    Assignee: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of certain drugs for treating nerve root injury
    Patent number: 7115557
    Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
    Type: Grant
    Filed: August 22, 2002
    Date of Patent: October 3, 2006
    Assignee: Sciaticon AB
    Inventor: Kjell Olmarker